ARCHIVES

FDA News: FDA Approved A Supplemental New Drug Application For Nexavar Tablets (Sorafenib) For The Treatment Of Patients With Locally Recurrent Or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory To Radioactive Iodine Treatment.

This article is from The Cancer Letter archive.

Vol. 39 No. 45 | December 17, 2013

Download PDF Visit The Full Archive

Related Articles

Cooperative group Outreach Extended Three ears, Gets Extra $1 Million, Up to Four More Awards

October 28, 1983

Community Assn. Meeting Includes Provocative Workshops

January 31, 1975

Center Core Grants Picture Less Bleak; Competing Renewals To Receive 50% Of Recommended Increases

January 4, 1980

NCI Advisors Approve Expansion Of CCOPs, Minority-Based CCOPs; Approve Reissuance Of BMT Network RFA, RFPs For Preclinical Drug Studies

November 13, 2009

Bernard Fisher Says Mistake Was Not Publishing Sooner

April 22, 1994

Aranesp Approval Introduces Competition To $1.8 Billion U.S. Cancer Anemia Market

August 2, 2002